Small molecules targeting aberrant STAT3 activity: killing breast tumour cells and inducing an anti-tumour immune response.

针对异常 STAT3 活性的小分子：杀死乳腺肿瘤细胞并诱导抗肿瘤免疫反应。

• 批准号: 355181
• 负责人: Gunning Patrick T
• 金额: $ 56.84万
• 依托单位: University of Toronto Mississauga (ON)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-10-01 至 2020-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=355181&lang=en
• 关键词: Breast Cancer Research; Drug Discovery; Her2+ Breast Cancer; Immunotherapeutic; Medicinal Chemistry; Triple Negative Breast Cancer

Here, we describe a class of novel drug-like molecules that potently and selectively kill both Her2+ and triple negative breast cancer cells over normal healthy cells. These molecules target a protein called STAT3, that has been shown to play a key role i

在这里，我们描述了一类新的药物样分子，有效地和选择性地杀死Her2+和三阴性乳腺癌细胞超过正常的健康细胞。这些分子靶向一种名为STAT3的蛋白质，该蛋白质已被证明在肿瘤发生中起关键作用。